Corvus Q3 net loss $10.7M, cash $76.3M; mupadolimab trials enrolling

Corvus Pharmaceuticals, Inc.

2022-Q3 EPS reported -$0.84

Net loss for Q3 2021 was $10.7M vs $9.8M in Q3 2020; R&D expenses $7.0M vs $6.6M.
Cash, equivalents and marketable securities $76.3M at Sept 30, 2021, up $32.0M from Dec 31, 2020; FY 2021 cash burn guided ~$36M.
Two Phase 1b/2 trials of mupadolimab + pembrolizumab enrolling: relapsed NSCLC (n=15) and HPV+ HNSCC (n=15); results expected 2022.
Angel Pharma received IND approval in China for CPI-818 Phase 1/1b in T-cell lymphoma; trial to open early 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.